Cargando…

Effect of Fecal Microbiota, Live-Jslm (REBYOTA [RBL]) on Health-Related Quality of Life in Patients With Recurrent Clostridioides difficile Infection: Results From the PUNCH CD3 Clinical Trial

BACKGROUND: Recurrence of Clostridioides difficile infection (rCDI) is common, prolonging disease morbidity and leading to poor quality of life. We evaluated disease-specific health-related quality of life (HRQL) in patients with rCDI treated with fecal microbiota, live-jslm (REBYOTA [RBL]; Rebiotix...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garey, Kevin W, Dubberke, Erik R, Guo, Amy, Harvey, Adam, Yang, Min, García-Horton, Viviana, Fillbrunn, Mirko, Wang, Hongjue, Tillotson, Glenn S, Bancke, Lindy L, Feuerstadt, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10411038/ https://www.ncbi.nlm.nih.gov/pubmed/37564743 http://dx.doi.org/10.1093/ofid/ofad383

Ejemplares similares

Safety of fecal microbiota, live-jslm (REBYOTA(™)) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials
por: Lee, Christine, et al.
Publicado: (2023)

Retrospective Analysis of the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA(TM)) Administered Under Enforcement Discretion to Patients With Clostridioides difficile Infection
por: Feuerstadt, Paul, et al.
Publicado: (2023)

522. Significant Improvement in Health-Related Quality of Life (HRQL) with RBX2660: Results from a Phase 3 Randomized, Placebo-Controlled Trial in Recurrent Clostridioides Difficile Infection (PUNCH CD3)
por: Feuerstadt, Paul, et al.
Publicado: (2022)

366. Association Between Gut Microbiota and Health-Related Quality of Life in Patients with Recurrent Clostridioides difficile Infection: Results from the PUNCH CD3 Clinical Trial
por: Feuerstadt, Paul, et al.
Publicado: (2023)

Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US
por: Lodise, Thomas, et al.
Publicado: (2023)

Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections
por: Orenstein, Robert, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA
por: Lodise, Thomas, et al.
Publicado: (2023)

Effect of fecal microbial transplantation on Clostridioides difficile infection: dysbiosis, metabolites and health related quality of life
por: Garey, Kevin W, et al.
Publicado: (2023)

Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent Clostridioides difficile Infection in Older Adults With Underlying Comorbidities
por: Tillotson, Glenn, et al.
Publicado: (2022)

706. An Ad Hoc Subgroup Analysis of a Phase 3, Open-Label Study Indicates Efficacy and Safety of Fecal Microbiota, Live-jslm in Participants With Recurrent Clostridioides difficile Infection and Renal Impairment
por: Fischer, Monika, et al.
Publicado: (2023)

Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection
por: Khanna, Sahil, et al.
Publicado: (2022)

Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection
por: Khanna, Sahil, et al.
Publicado: (2022)

Patient Perception of Route of Rectal Administration of Live Biotherapeutic Product for Recurrent Clostridioides difficile Infection
por: Feuerstadt, Paul, et al.
Publicado: (2023)

Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost Synthesis
por: Reveles, Kelly R., et al.
Publicado: (2023)

2235. Fecal Biomarkers for Clostridioides difficile Infection in Cancer Patients
por: Olvera, Adilene, et al.
Publicado: (2019)

167. Efficacy of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioides difficile Infection: Data from Five Prospective Clinical Studies
por: Bancke, Lindy, et al.
Publicado: (2021)

702. Efficacy of Fecal Microbiota, Live-jslm After Receipt of Non–Clostridioides difficile Infection Antibiotics: Post Hoc Subgroup Analysis of a Phase 2 Open-Label Trial
por: Reveles, Kelly R, et al.
Publicado: (2023)

Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection
por: Feuerstadt, Paul, et al.
Publicado: (2021)

1657 Who Seeks a Fecal Microbiota Transplant for Recurrent C. difficile Infection?: Patient Profile of the PUNCH CD Study
por: Orenstein, Robert, et al.
Publicado: (2014)

Evolution of clinical guidelines for antimicrobial management of Clostridioides difficile infection
por: Chaar, Abdelkader, et al.
Publicado: (2021)

236. Treatment of Recurrent Clostridioides difficile Infection With RBX2660 in Patients ≥ 65 Years Old With Underlying Comorbidities
por: Tillotson, Glenn S, et al.
Publicado: (2022)

Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent Clostridioides difficile infection from the open-label PUNCH CD study
por: Langdon, Amy, et al.
Publicado: (2021)

The Importance of a Broad Consortium of Bacteria for a Healthy Gastrointestinal tract: A Narrative Review of the Live Biotherapeutic Product REBYOTA
por: Tillotson, Glenn, et al.
Publicado: (2023)

Gut microbiota and microbiota-based therapies for Clostridioides difficile infection
por: Chopra, Teena, et al.
Publicado: (2023)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

Fecal Microbiota of Toxigenic Clostridioides difficile-Associated Diarrhea
por: Hernández, Marta, et al.
Publicado: (2019)

Fecal microbiota transplantation beyond Clostridioides difficile infections
por: Wortelboer, Koen, et al.
Publicado: (2019)

Fecal Microbiota Transplantation beyond Clostridioides Difficile Infection
por: Moon, Chang Mo, et al.
Publicado: (2021)

Transitions of care in Clostridioides difficile infection: a need of the hour
por: Khanna, Sahil, et al.
Publicado: (2022)

Emerging Options for the Prevention and Management of Clostridioides difficile Infection
por: Gonzales-Luna, Anne J., et al.
Publicado: (2023)

Usefulness of Fecal Calprotectin in the Management of Patients with Toxigenic Clostridioides difficile
por: Suarez-Carantoña, Cecilia, et al.
Publicado: (2021)

Fecal host biomarkers predicting severity of Clostridioides difficile infection
por: Golizeh, Makan, et al.
Publicado: (2021)

Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls
por: Sandhu, Avnish, et al.
Publicado: (2021)

471. Prevalence and Characteristics of Clostridioides difficile Infection in Bangladesh
por: Sofjan, Amelia K, et al.
Publicado: (2018)

2380. Fecal Collinsella Abundance is Negatively Associated with Toxin A/B Production in Cancer Patients with Clostridioides difficile
por: A. Francisco, Denise Marie, et al.
Publicado: (2019)

Role of the microbiome in essential metabolism in the human gut and its implications for Clostridioides difficile infection
por: Chopra, Teena, et al.
Publicado: (2023)

752. Costs Attributable to Clostridioides difficile Infection in the Presence of Differential Mortality
por: Sahrmann, John, et al.
Publicado: (2021)

685. Early Experience with a Simple Administration of a Novel Fecal Microbiome Replacement for Prevention of Recurrent Clostridioides difficile
por: Hengel, Richard L, et al.
Publicado: (2023)

Immunological mechanisms of fecal microbiota transplantation in recurrent Clostridioides difficile infection
por: Soveral, Lucas F, et al.
Publicado: (2022)

The value of fecal calprotectin in Clostridioides difficile infection: A systematic review
por: Wen, Bao-Jiang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fibojm4vhm2731374vvc7nvmmu